Unfortunately FDA approval for LOCAMETZ will spell very bad news for Telix. Basically this means market penetration for Illuccix will now be considerably less than initially expected and Novartis is now expected to dominate the market for diagnostic imaging for prostate cancer as well.
It looks like Novartis will require Pluvicto to be used in conjunction with LOCAMETZ based on the labeling.
"FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions."
"LOCAMETZ® (kit for the preparation of gallium Ga 68 gozetotide injection), after radiolabeling with gallium-68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer."
https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer
https://www.hcp.novartis.com/products/locametz/psma-pet-ct/
Good luck to all here.
Unfortunately FDA approval for LOCAMETZ will spell very bad news...
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
-0.480(2.60%) |
Mkt cap ! $6.023B | |||
| Open | High | Low | Value | Volume |
| $18.30 | $18.44 | $17.97 | $17.04M | 940.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3545 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.03 | 2030 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |